Barclays PLC Buys 39,506 Shares of Harrow, Inc. (NASDAQ:HROW)

Barclays PLC lifted its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 301.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,593 shares of the company’s stock after acquiring an additional 39,506 shares during the quarter. Barclays PLC owned approximately 0.15% of Harrow worth $2,365,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in HROW. Oppenheimer & Co. Inc. acquired a new stake in Harrow during the 3rd quarter valued at approximately $1,267,000. Penserra Capital Management LLC bought a new stake in shares of Harrow in the 3rd quarter valued at $1,986,000. SG Americas Securities LLC acquired a new stake in shares of Harrow during the third quarter worth $534,000. Semanteon Capital Management LP bought a new position in Harrow during the third quarter worth $686,000. Finally, Creative Planning lifted its holdings in Harrow by 96.8% in the second quarter. Creative Planning now owns 29,486 shares of the company’s stock valued at $616,000 after buying an additional 14,500 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HROW has been the subject of a number of recent analyst reports. Craig Hallum increased their price target on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th. Lake Street Capital upped their target price on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, B. Riley lowered their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Stock Down 0.5 %

HROW opened at $33.83 on Thursday. Harrow, Inc. has a fifty-two week low of $9.13 and a fifty-two week high of $59.23. The firm has a market capitalization of $1.20 billion, a P/E ratio of -35.99 and a beta of 0.69. The company’s 50-day moving average is $43.82 and its 200 day moving average is $37.01. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.